Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DUSP10 | Q9Y6W6 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18431492 | 0.86 | L3MBTL1 (0.38) | L3MBTL1ALOX15KMT2ADUSP10MAPK9 | |
| SCHEMBL18431830 | 0.81 | L3MBTL1 (0.40) | L3MBTL1ALOX15KMT2ANPC1RAB9A | |
| SCHEMBL23767706 | 0.72 | — | — | |
| SCHEMBL12263926 | 0.72 | ALDH1A1 (0.38) | L3MBTL1ALOX15KMT2ADUSP10NPC1 | |
| SCHEMBL12656591 | 0.71 | ALOX15 (0.35) | L3MBTL1ALOX15KMT2ADUSP10ALDH1A1 | |
| SCHEMBL12933370 | 0.70 | HDAC3 (0.40) | L3MBTL1ALOX15KMT2ADUSP10SMN1; SMN2 | |
| SCHEMBL18470067 | 0.70 | — | — | |
| SCHEMBL24285815 | 0.68 | MAPK9 (0.35) | L3MBTL1MAPK9MAPK10 | |
| SCHEMBL19503784 | 0.66 | MAPK9 (0.40) | L3MBTL1RAB9AMAPK9MAPK10 | |
| SCHEMBL18737447 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189794-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2019-01-29 | — | — | US | disclosed |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189794-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | L3MBTL1 3899/4885ALOX15 979/4885KMT2A 3318/4885 |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | L3MBTL1 3899/4885ALOX15 979/4885KMT2A 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.